which represents mAb H100-30 [3 (25) , anti-K k's, and cross-reactive with r, b, and q, and 2.4G2, anti-mouse IgG2bFc receptor (Fc~,R) (26) .
Cells. Spleen cells were isolated from B10 or B10.A mice and treated with either 10 mM trinitrobenzene sulfonate (TNBS) (Pierce Chemical Co., Rockford, IL) or 0.5 mM fluorescein isothiocyanate (FITC) (Research Organics, Cleveland, OH) as previously described (3) . The R1 (TL +) and R1 (TL-) cell lines were obtained from Dr. Robert Hyman of The Salk Institute, San Diego, CA, and were grown in tissue culture. The R1 (TL +) line was originally derived from a spontaneous thymoma in a C58 mouse, and expresses the H-2 k haplotype. The R 1 (TL-) variant was obtained by selecting mutagenized R 1 (TL ÷) cells against TL expression. It has concomitantly lost the ability to express MHC class I molecules, but not other cell surface antigens (27) . Cells from both lines were modified with 10 mM TNBS, using the same procedure as for the spleen cells. Both spleen and lymphoma cells were centrifuged over Lympholyte M (Cedarlane Laboratories, Hornby, Ontario) to remove dead cells• Radioiodination and Binding Assay. The purification and iodination of mAb, and the binding assay is described in detail elsewhere (28) . Briefly, purified mAb were radiolabeled by a modified chloramine T method (28) . Splenic or R1 lymphocytes were iabeledowith 5*Cr, then mixed with graded concentrations of *~SI-antibody. After incubation at 4 C in medium containing 0.2% sodium azide for a time predetermined to allow the system to reach equilibrium, the cells were sedimented through a mixture of phthalate oils in 400-~zl microfuge tubes (28) . The numbers of molecules of bound antibody/cell were calculated 1~25 51 from the I/ Cr ratios in the tips of the microfuge tubes. Nonsaturable binding was determined from controls containing a large excess of unlabeled antibody in addition to the labeled antibody and cells, and was subtracted from the total binding• Since the phthalate oil technique does not require a wash step, it measures both high and low avidity
mteracuons. In order to assure accurate cell counts of Cr-labeled ceils, three aliquots of the same cell sample were counted microscopically. The resulting values of 51Cr cpm/cell were estimated to be accuate to _+ 5%. (Fig. 1A) . A similar enhancement of 36.7.5 binding was not detected following hapten modification with FITC ( Fig. 1 A) . Two additional anti-K k reagents, 11.4.1 (Fig. 1B ) and 100.3 ( Fig. 1 C) showed similar increases in binding to TNP-modified spleen cells when compared with unmodified B10.A spleen cells. To assess whether any anti-class I mAb would exhibit increased binding after TNBS modification, a mAb directed against the D a molecule (27.11.13) was tested in this system. In contrast to the anti-K k monoclonals, this antibody bound to similar extents to unmodified, TNP-modifled, or FITC-modified spleen cells (Fig. 1 D) . To exclude the possibility that the anti-K k antibodies cross-reacted with TNP, 36.7.5 was incubated with B 10.A-TNP cells in the presence or absence of 0.25 mM DNP+aminocaproate (a high concentration of inhibitor). No inhibition of the anti-K k antibody binding was observed in the presence of the hapten (Fig.  1 E) . Free hapten, however, did inhibit the binding of anti-DNP antibody to B10.A-TNP cells (Fig. 1F) . Together, these data indicate that the increase in 36. (Fig. 2) , a predominant Kk-restricted CTL response was induced. Thus, if TNP-modification of B10.A cell surface products results in the presence of additional Kk-like determinants, this could contribute to the predominant K k restriction of anti-TNP self CTL responses.
Generation of CTL and Assay for Cytotoxicity Against TNP-Self
Since extensive cross-reactivity has been reported between H-2 alloantigens and TNP-self by CTL from H-2 b mice (29-35), we investigated whether anti-K k mAb would recognize TNP-modified B10 cells. The results of Fig. 3A indicate that 36.7.5, which does not bind to unmodified B10 spleen cells, does in fact (Fig. 3/3 ). However, two mAb directed against D b antigens, 27.11.13 and 28.14.8, failed to show increased binding to B 10 cells after TNP modification (Fig. 3, C and D) . Although we have not made an extensive survey of the binding of 36.7.5 to TNP-modified spleen cells of various haplotypes, we have observed that TNP-modified ATL spleen cells and TNP-B10 cells (data not shown) bind 36.7.5 to a similar extent. This is of interest because the 36.7.5 antibody was derived from ATL spleen cells (i.e., ATL anti-AAL).
To determine whether the enhanced binding of anti-K k mAb by TNP-modified cells was dependent on expression of class I MHC molecules, the R1 (TL +) and R1 (TL-) cell lines were modified with TNP and tested for 36.7.5 binding. As shown in Fig. 4, 36 .7.5 bound saturably to the TL + cell line and exhibited enhanced binding to TNP-modified R1 (TL+). In contrast, the TL-line, a variant that does not express class I molecules (27) , did not bind 36.7.5, either unmodified or when modified with TNP. These data indicate that class I MHC molecules are required to obtain enhanced binding of anti-K k mAb to TNPmodified H-2 k cells.
Discussion
The data presented in this study demonstrate that modification of cell surface products with TNP can result in the formation of neooantigenic determinants that mimic H-2K k epitopes in their ability to bind anti-K k mAb. The enhanced binding ofanti-K k mAb to TNP-modified cells is not due to a heteroclitic reaction with the TNP groups, since binding is not blocked by free hapten (Figs. 1 and 3 ). Furthermore, it is highly unlikely that three different anti-K k mAb would each cross-react with some neo-determinant structurally distinct from the K k epitope to which it was raised. Rather, the simplest and most likely interpretation of the data is that the neo-determinants that are produced by TNP modification of B 10 and B 10.A spleen cells are structurally similar to K k epitopes.
The cross-reactivity of the anti-K k mAb with TNP-modified B10 cells (Fig. 3 ) parallels the well-established cross-reaction that CTL raised against allogeneic stimulators exhibit when tested against TNP-self, especially in the B10 strain (29) . It has also been demonstrated, both in bulk cultures (34) and at the clonal level (33) , that B10 spleen cells stimulated with B10-TNP can lyse unmodified H-2 k targets. The similarities in the cross-reactions exhibited by both CTL and antibodies suggest that the CTL may recognize the same neo-antigens that are detected by the mAb.
The nature of the neo-determinants is unknown, although the data of Fig. 4 suggest that they require the expression of MHC class I molecules, since these neo-determinants were not detected on the TNP-modified class I negative variant line. One possibility is that the neo-antigens arise from TNP modification of class I molecules themselves. TNP derivatization of these products has been shown to occur (36) , and since considerable homology between class I allelic products has been demonstrated (37), subtle modification of H-2 b MHC products might result in the formation of Kk-like determinants. Alternatively, TNP-modified nonclass I molecules might interact on the cell surface with class I molecules and induce a change in epitope expression. This latter hypothesis is perhaps more attractive, since it provides a molecular basis for the function of MHC class I antigens, namely to serve as signal proteins that CTL could utilize to detect changes in cell surfaces resulting from, for example, viral infection.
We do not yet know whether the appearance of neo-determinants occurs only with TNP modification, or is a more general phenomenon that could involve other haptens or viruses. Some studies have reported that vitally infected murine (38) and human (39) cells can bind alloantibodies, while other studies (32) have shown that CTL raised against virally infected self can cross-react with uninfected allogeneic cells. Recently it has been reported that neo-antigens that resemble HLA allodeterminants can be detected with mAb when human leukocytes are infected with human T cell leukemia virus (40) . Finally, it has also been found (41) that a majority of mAb raised against virally infected syngeneic cells would not bind to either the virus alone or to uninfected syngeneic cells, but would react with infected cells. One explanation of these results is that the cell surface modifications resulting from viral infection included the production of class Ilike neo-antigenic determinants, and that the mAb were directed against these determinants. It would be interesting to know whether such antibodies would bind to uninfected allogeneic cells.
The approach used in the present study may be valuable in elucidating the structural changes that can occur when class I molecules interact with foreign antigens on cell surfaces. Our data are consistent with the idea that antigeninduced altered regions on class I molecules serve as recognition sites for CTL and determine whether or not lysis will occur. 
